AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study

Key Takeaways AstraZeneca reported positive phase III Bax24 data in patients with resistant hypertension.Baxdrostat achieved a significant drop in 24-hour average systolic blood pressure versus placebo.Baxdrostat was well tolerated, and AstraZeneca plans to share results with global regulators.AstraZeneca (AZN) announced positive top-line data from the phase III Bax24 study evaluating the safety, tolerability and efficacy of its investigational candidate, baxdrostat, in patients with resistant hypertension. ...